N1VO34:BVMF
Novo
24,00 BRL
0,00%
(0,00) 1D
9. okt., 17:05:00 GMT -3 · BRL
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za N1VO34 …
Odpri
24,20 BRL
Visoka
24,20 BRL
Nizka
23,80 BRL
Tržna kapitalizacija
128,45 mrd.
Povprečni promet
35,62 tis.
Promet
8,94 tis.
52-tedenski najvišji tečaj
42,43 BRL
52-tedenski najnižji tečaj
22,90 BRL
Št. izdanih delnic
3,39 mrd.
Št. zaposlenih
67 tis.
Odpri
24,20 BRL
Visoka
24,20 BRL
Nizka
23,80 BRL
Tržna kapitalizacija
128,45 mrd.
Povprečni promet
35,62 tis.
Promet
8,94 tis.
52-tedenski najvišji tečaj
42,43 BRL
52-tedenski najnižji tečaj
22,90 BRL
Št. izdanih delnic
3,39 mrd.
Št. zaposlenih
67 tis.
Novice
Iz spletnih virov in novičarskih partnerjev
The Motley Fool
·
pred 23 urami
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Simply Wall Street
·
pred 1 dnevom
Novo Nordisk (NVO) Stock May Trade Below Fair Value After GLP 1 Expansion Plans
Yahoo Finance
·
pred 2 dnevoma
Novo Nordisk (NVO) Raised Its Outlook, Then Aimed for Average Growth
Traders Union
·
pred 2 dnevoma
Novo Nordisk stock support test at $37.43: Technical outlook
Profil
Novo is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark's domestic economy, and it became the highest valued company in Europe. Wikipedia
Vizitka: Novo
Generalni direktorMaziar Mike Doustdar
Št. zaposlenih66,7 tis.
Ustanovljeno21. dec. 1923
SedežBagsværd, Capital Region of Denmark, Danska
Sektor-
Spletno mestonovonordisk.com